BACKGROUND: Recent evidence suggests carbohydrate intake may influence prostate cancer biology. We tested whether a no-carbohydrate ketogenic diet (NCKD) would delay prostate cancer growth relative to Western and low-fat diets in a xenograft model. METHODS: Seventy-five male SCID mice were fed a NCKD (84% fat-0% carbohydrate-16% protein kcal), low-fat (12% fat-72% carbohydrate-16% protein kcal), or Western diet (40% fat-44% carbohydrate-16% protein kcal). Low-fat mice were fed ad libitum and the other arms fed via a modified-paired feeding protocol. After 24 days, all mice were injected with LAPC-4 cells and sacrificed when tumors approached 1,000 mm(3). RESULTS: Despite consuming equal calories, NCKD-fed mice lost weight (up to 15% body weight) relative to low-fat and Western diet-fed mice and required additional kcal to equalize body weight. Fifty-one days after injection, NCKD mice tumor volumes were 33% smaller than Western mice (rank-sum, P = 0.009). There were no differences in tumor volume between low-fat and NCKD mice. Dietary treatment was significantly associated with survival (log-rank, P = 0.006), with the longest survival among the NCKD mice, followed by the low-fat mice. Serum IGFBP-3 was highest and IGF-1:IGFBP-3 ratio was lowest among NCKD mice while serum insulin and IGF-1 levels were highest in Western mice. NCKD mice had significantly decreased hepatic fatty infiltration relative to the other arms. CONCLUSIONS: In this xenograft model, despite consuming more calories, NCKD-fed mice had significantly reduced tumor growth and prolonged survival relative to Western mice and was associated with favorable changes in serum insulin and IGF axis hormones relative to low-fat or Western diet. (c) 2007 Wiley-Liss, Inc.
BACKGROUND: Recent evidence suggests carbohydrate intake may influence prostate cancer biology. We tested whether a no-carbohydrate ketogenic diet (NCKD) would delay prostate cancer growth relative to Western and low-fat diets in a xenograft model. METHODS: Seventy-five male SCID mice were fed a NCKD (84% fat-0% carbohydrate-16% protein kcal), low-fat (12% fat-72% carbohydrate-16% protein kcal), or Western diet (40% fat-44% carbohydrate-16% protein kcal). Low-fat mice were fed ad libitum and the other arms fed via a modified-paired feeding protocol. After 24 days, all mice were injected with LAPC-4 cells and sacrificed when tumors approached 1,000 mm(3). RESULTS: Despite consuming equal calories, NCKD-fed mice lost weight (up to 15% body weight) relative to low-fat and Western diet-fed mice and required additional kcal to equalize body weight. Fifty-one days after injection, NCKD micetumor volumes were 33% smaller than Western mice (rank-sum, P = 0.009). There were no differences in tumor volume between low-fat and NCKD mice. Dietary treatment was significantly associated with survival (log-rank, P = 0.006), with the longest survival among the NCKD mice, followed by the low-fat mice. Serum IGFBP-3 was highest and IGF-1:IGFBP-3 ratio was lowest among NCKD mice while serum insulin and IGF-1 levels were highest in Western mice. NCKD mice had significantly decreased hepatic fatty infiltration relative to the other arms. CONCLUSIONS: In this xenograft model, despite consuming more calories, NCKD-fed mice had significantly reduced tumor growth and prolonged survival relative to Western mice and was associated with favorable changes in serum insulin and IGF axis hormones relative to low-fat or Western diet. (c) 2007 Wiley-Liss, Inc.
Authors: Melanie Walker; Kristan J Aronson; Will King; James W L Wilson; Wenli Fan; Jeremy P W Heaton; Andrew MacNeily; J Curtis Nickel; Alvaro Morales Journal: Int J Cancer Date: 2005-09-10 Impact factor: 7.396
Authors: Carole S Watson; Peter Bialek; Makoto Anzo; Javad Khosravi; Siu-Pok Yee; Victor K M Han Journal: Endocrinology Date: 2005-11-17 Impact factor: 4.736
Authors: E Bidoli; R Talamini; C Bosetti; E Negri; D Maruzzi; M Montella; S Franceschi; C La Vecchia Journal: Ann Oncol Date: 2005-01 Impact factor: 32.976
Authors: Michael L Dansinger; Joi Augustin Gleason; John L Griffith; Harry P Selker; Ernst J Schaefer Journal: JAMA Date: 2005-01-05 Impact factor: 56.272
Authors: Thomas L Halton; Walter C Willett; Simin Liu; JoAnn E Manson; Christine M Albert; Kathryn Rexrode; Frank B Hu Journal: N Engl J Med Date: 2006-11-09 Impact factor: 91.245
Authors: Christopher D Gardner; Alexandre Kiazand; Sofiya Alhassan; Soowon Kim; Randall S Stafford; Raymond R Balise; Helena C Kraemer; Abby C King Journal: JAMA Date: 2007-03-07 Impact factor: 56.272
Authors: Jessica C Lloyd; Jodi A Antonelli; Tameika E Phillips; Elizabeth M Masko; Jean-Alfred Thomas; Susan H M Poulton; Michael Pollak; Michael Pollack; Stephen J Freedland Journal: J Urol Date: 2010-02-20 Impact factor: 7.450
Authors: Kristine Pelton; Christine M Coticchia; Adam S Curatolo; Carl P Schaffner; David Zurakowski; Keith R Solomon; Marsha A Moses Journal: Am J Pathol Date: 2014-07 Impact factor: 4.307
Authors: Kathryn N Phoenix; Frank Vumbaca; Melissa M Fox; Rebecca Evans; Kevin P Claffey Journal: Breast Cancer Res Treat Date: 2009-11-22 Impact factor: 4.872
Authors: Jorge Caso; Elizabeth M Masko; Jean A Thomas Ii; Susan H Poulton; Mark Dewhirst; Salvatore V Pizzo; Stephen J Freedland Journal: Prostate Date: 2012-10-04 Impact factor: 4.104
Authors: Amir Zahra; Melissa A Fath; Emyleigh Opat; Kranti A Mapuskar; Sudershan K Bhatia; Daniel C Ma; Samuel N Rodman; Travis P Snyders; Catherine A Chenard; Julie M Eichenberger-Gilmore; Kellie L Bodeker; Logan Ahmann; Brian J Smith; Sandy A Vollstedt; Heather A Brown; Taher Abu Hejleh; Gerald H Clamon; Daniel J Berg; Luke I Szweda; Douglas R Spitz; John M Buatti; Bryan G Allen Journal: Radiat Res Date: 2017-04-24 Impact factor: 2.841